Telix Pharmaceuticals moved to lock in manufacturing capacity and an R&D pipeline by agreeing to buy ITM Isotope Technologies Munich in a deal worth $1.65 billion upfront, with additional milestones. The transaction combines ITM’s radioisotope manufacturing footprint with Telix’s development programs, positioning the combined company to compete more directly in the radiopharmaceutical category that has been dominated by Novartis. The transaction milestones hinge on a recently rejected drug, adding a clear regulatory execution element to the timeline. Even with the dependency risk, multiple analysts characterized the acquisition as a strategic expansion into a rival’s territory, underscoring investor focus on radiopharma scale, supply reliability, and late-stage leverage. Separately, STAT+ reported that the merger follows one “surprise” FDA rejection for an ITM drug, emphasizing that regulatory outcomes remain decisive for deal economics. For the sector, the message is that radiopharma consolidation is no longer optional—companies are trying to secure both isotope supply and clinical development continuity at once.